Inclusion Criteria:

- Meets one of the following sets of criteria:

- Histologically and/or cytologically confirmed solid malignancy

- Metastatic or unresectable disease

- Disease for which standard curative or palliative measures do not exist or
are no longer effective

- Histologically and/or cytologically confirmed adenocarcinoma of the pancreas
(for patients in the expansion cohort)

- Locally advanced or metastatic disease

- No prior chemotherapy for advanced disease

- Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1
dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques
or as ≥ 10 mm with spiral CT scan

- No known brain metastases

- ECOG performance status (PS) 0-1 (Karnofsky PS 60-100%)

- Life expectancy > 12 weeks

- Hemoglobin ≥ 90 g/L (or ≥ 9 g/dL)

- Leukocytes ≥ 3,000/mm^3

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Total bilirubin ≤ 1.25 times upper limit of normal (ULN)

- AST/ALT ≤ 1.5 times ULN

- Serum creatinine =< ULN OR creatinine clearance ≥ 60 mL/min

- No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or
hypokalemia, defined as less than the lower limit of normal despite adequate
electrolyte supplementation

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use two forms of adequate contraception (i.e., barrier
contraception and one other method of contraception) for ≥ 4 weeks before, during,
and for ≥ 12 months after completion of study treatment

- Able to swallow medication

- No malabsorption syndrome or other condition that would interfere with intestinal
absorption

- No uncontrolled concurrent illness including, but not limited to, any of the
following:

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia other than chronic, stable atrial fibrillation

- Psychiatric illness or social situations that would limit compliance with study
requirements

- No baseline QTc > 450 msec (for male patients) or > 470 msec (for female patients)

- No history of risk factors for QT interval prolongation including, but not limited
to, a family or personal history of any of the following:

- Long QT syndrome

- Recurrent syncope without known etiology

- Sudden unexpected death

- No history of torsade de pointes or other significant cardiac arrhythmias or the need
for concomitant meds with known potential to prolong QT interval or antiarrhythmics

- No diarrhea ≥ grade 2 not under control with standard anti-diarrhea medications

- No serologic positivity for hepatitis A, B, or C

- No history of liver disease or other forms of hepatitis or cirrhosis

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to gamma-secretase inhibitor RO4929097 or to gemcitabine
hydrochloride

- Female patients may not donate ova during or after completion of study treatment

- Male patients may not donate sperm during and for ≥ 12 months after completion of
study treatment

- Patients may not donate blood during and for ≥ 12 months after completion of study
treatment

- No other concurrent investigational or commercial agents or therapies administered
with the intent to treat the patient's malignancy

- Any number of prior therapies allowed

- No prior therapy with a Notch inhibitor

- At least 4 weeks since prior radiotherapy, chemotherapy, or systemic therapy (6 weeks
if the last regimen included nitrosourea or mitomycin C) and recovered

- Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for
symptomatic palliation

- Patients in the expansion cohort must meet the following criteria:

- No prior chemotherapy for advanced disease except for fluorouracil (with or
without folinic acid) or gemcitabine hydrochloride given concurrently with
radiotherapy as a "radiosensitizer"

- At least 6 months since prior adjuvant gemcitabine hydrochloride

- Prior radiotherapy for the management of local disease allowed provided > 4
weeks have elapsed since the last radiation treatment and all toxicities have
resolved

- Patients who have had radiotherapy to their sole site of disease are eligible
provided they have documented progression of that lesion before study
registration

- Recovered from side effects of previous systemic anticancer therapy to ≤ CTCAE grade
2

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No concurrent medications with narrow therapeutic indices that are metabolized by
cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)

- No concurrent medications with known potential to prolong QT interval

- No concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4

- No concurrent medications or food that may interfere with the metabolism of
gamma-secretase inhibitor RO4929097, including ketoconazole and grapefruit or
grapefruit juice

- No other concurrent investigational agents